111 related articles for article (PubMed ID: 18575956)
21. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
Valensi P; Cosson E
Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
[TBL] [Abstract][Full Text] [Related]
22. Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes.
Ma Z; Christiansen JS; Laursen T; Lauritzen T; Frystyk J
Eur J Endocrinol; 2014 Oct; 171(4):471-9. PubMed ID: 25005937
[TBL] [Abstract][Full Text] [Related]
23. Comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes.
White NH; Chase HP; Arslanian S; Tamborlane WV;
Diabetes Care; 2009 Mar; 32(3):387-93. PubMed ID: 19106380
[TBL] [Abstract][Full Text] [Related]
24. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes.
Hershon KS; Blevins TC; Mayo CA; Rosskamp R
Endocr Pract; 2004; 10(1):10-7. PubMed ID: 15251616
[TBL] [Abstract][Full Text] [Related]
25. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.
Heinemann L; Linkeschova R; Rave K; Hompesch B; Sedlak M; Heise T
Diabetes Care; 2000 May; 23(5):644-9. PubMed ID: 10834424
[TBL] [Abstract][Full Text] [Related]
26. Insulin glargine.
Campbell RK; White JR; Levien T; Baker D
Clin Ther; 2001 Dec; 23(12):1938-57; discussion 1923. PubMed ID: 11813930
[TBL] [Abstract][Full Text] [Related]
27. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
28. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
[TBL] [Abstract][Full Text] [Related]
29. Spotlight on insulin glargine in type 1 and 2 diabetes mellitus.
McKeage K; Goa KL
Treat Endocrinol; 2002; 1(1):55-8. PubMed ID: 15765621
[TBL] [Abstract][Full Text] [Related]
30. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Heise T; Nosek L; Rønn BB; Endahl L; Heinemann L; Kapitza C; Draeger E
Diabetes; 2004 Jun; 53(6):1614-20. PubMed ID: 15161770
[TBL] [Abstract][Full Text] [Related]
31. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes.
Witthaus E; Stewart J; Bradley C
Diabet Med; 2001 Aug; 18(8):619-25. PubMed ID: 11553198
[TBL] [Abstract][Full Text] [Related]
32. Insulin glargine: a new long-acting insulin product.
Reinhart L; Panning CA
Am J Health Syst Pharm; 2002 Apr; 59(7):643-9. PubMed ID: 11944604
[TBL] [Abstract][Full Text] [Related]
33. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
[TBL] [Abstract][Full Text] [Related]
34. Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice.
Nagel JM; Staffa J; Renner-Müller I; Horst D; Vogeser M; Langkamp M; Hoeflich A; Göke B; Kolligs FT; Mantzoros CS
Horm Cancer; 2010 Dec; 1(6):320-30. PubMed ID: 21761363
[TBL] [Abstract][Full Text] [Related]
35. Use of insulin glargine in Japanese patients with type 1 diabetes.
Yamamoto-Honda R; Takahashi Y; Yoshida Y; Hara Y; Kawai A; Kitazato H; Tanaka T; Kajio H; Kikuchi M; Akanuma Y; Noda M
Intern Med; 2007; 46(13):937-43. PubMed ID: 17603230
[TBL] [Abstract][Full Text] [Related]
36. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes.
Lipska KJ; Parker MM; Moffet HH; Huang ES; Karter AJ
JAMA; 2018 Jul; 320(1):53-62. PubMed ID: 29936529
[TBL] [Abstract][Full Text] [Related]
37. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
[TBL] [Abstract][Full Text] [Related]
38. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
[TBL] [Abstract][Full Text] [Related]
39. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
Owens DR; Bolli GB
Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
[TBL] [Abstract][Full Text] [Related]
40. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.
Rosenstock J; Fonseca V; McGill JB; Riddle M; Hallé JP; Hramiak I; Johnston P; Davis M
Diabetologia; 2009 Sep; 52(9):1971-3. PubMed ID: 19609501
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]